{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McMiller TL"],"funding":["Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University","Clinical Center","Bristol Myers Squibb","Mark Foundation For Cancer Research"],"pagination":["e010201"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11580252"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(11)"],"pubmed_abstract":["Background
Gastric carcinomas (GC) are aggressive malignancies, and only ~15% of patients respond to anti-programmed cell death (ligand) 1 (PD-(L)1) monotherapy. However, Epstein-Barr virus (EBV)-associated GCs (~5-10% of GCs) often harbor PD-L1 and PD-L2 chromosomal amplifications and robust CD8+ T cell infiltrates, and respond at a high rate to anti-PD-1. The current study compares the tumor immune microenvironments (TiMEs) of EBV+ versus EBV(-) GCs.Methods
Over 1000 cases of primary invasive GCs were screened to identify 25 treatment-naïve specimens for study (11 EBV+, 14 EBV(-)). Quantitative immunohistochemistry (IHC) was conducted for markers of immune cell subsets and co-regulatory molecules. Gene expression profiling (GEP) was performed on RNAs isolated from macrodi"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy."],"pmcid":["PMC11580252"],"funding_grant_id":["N/A","NCI R01CA142779"],"pubmed_authors":["Xu K","Taube JM","Anders RA","McMiller TL","Lee J","Engle LL","Bhaijee F","Unsal-Kacmaz K","Berger AE","Besharati S","Yarchoan M","Zhu Q","Topalian SL"],"additional_accession":[]},"is_claimable":false,"name":"Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy.","description":"Background
Gastric carcinomas (GC) are aggressive malignancies, and only ~15% of patients respond to anti-programmed cell death (ligand) 1 (PD-(L)1) monotherapy. However, Epstein-Barr virus (EBV)-associated GCs (~5-10% of GCs) often harbor PD-L1 and PD-L2 chromosomal amplifications and robust CD8+ T cell infiltrates, and respond at a high rate to anti-PD-1. The current study compares the tumor immune microenvironments (TiMEs) of EBV+ versus EBV(-) GCs.Methods
Over 1000 cases of primary invasive GCs were screened to identify 25 treatment-naïve specimens for study (11 EBV+, 14 EBV(-)). Quantitative immunohistochemistry (IHC) was conducted for markers of immune cell subsets and co-regulatory molecules. Gene expression profiling (GEP) was performed on RNAs isolated from macrodi","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2025-04-04T01:20:51.643Z","creation":"2025-04-04T01:20:51.643Z"},"accession":"S-EPMC11580252","cross_references":{"pubmed":["39572160"],"doi":["10.1136/jitc-2024-010201"]}}